RAPTIVA Pages on BioPortfolio:

Biotechnology News RAPTIVA Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/RAPTIVA-news.htm...

BioPortfolio - Raptiva
Raptiva - BioPortfolio - Indepth. ... Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
...
http://www.bioportfolio.com/indepth/Raptiva.html...

BioPortfolio.com - BioWeb OMNITROPE SOMATROPIN RECOMBINANT isrupt ...
Home Contact Us Site Index Search [ Products -- Nutropin ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=se...

BioPortfolio - - Severe Adverse Event Reported in Raptiva(R) Patient
46000 patients treated with Raptiva(R) we want to ensure investigators and ... cannot be excluded that Raptiva(R) may have had a contributory role in the ...
http://www.bioportfolio.com/news/Severe_Adverse_Event_Report...

BioPortfolio - BioTrends Research Group, Inc. - Raptiva Withdrawal ...
BioTrends Research Group, Inc. - Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of US Dermatologists ...
http://www.bioportfolio.com/news/Raptiva_Withdrawal_Offers_U...

BioPortfolio - - European Medicines Agency Recommends Suspension ...
Recommends Suspension of Marketing Authorization for Raptiva(R). Tuesday 9 December 2008 ... http://www.prnewswire.co.uk/cgi/news/company?id=236465. ...
http://www.bioportfolio.com/news/European_Medicines_Agency_R...

Wong's BioTech Stock Report - focus on the pipeline Fabrazyme ...
Genentech will co-promote Xolair and Raptiva with Xoma (NASDAQ: XOMA) and Novartis AG ... While the odds of marketing approval looks promising for Raptiva
, ...
http://www.bioportfolio.com/news/biotechsage_6.htm...

Psoriasis: Biologics hope to reach 8mill undiagnosed sufferers
The current leading biologics are Biogen Idec and Genentech's Amevive; Serono, Genentech and XOMA's Raptiva; Wyeth and Amgen's Enbrel and Johnson and ...
http://www.bioportfolio.com/news/datamonitor_115.htm...

BioPortfolio - Biocorporate Search Antibody
We have a royalty interest in one approved therapeutic antibody, RAPTIVA® ( efalizumab),... www.xoma.com/ View full profile ...
http://www.bioportfolio.com/biocorporate/Antibody-companies....

BioPortfolio Limited Stakeholder Insight: Psoriasis - Biologics ...
Remicade and Raptiva are the clear favorites at third line 99 ... Raptiva's safety profile continues to signal doom for the brand 114 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_19.html...

Results from other life science and pharmaceutical sites:

Genentech: Newsroom: Press Releases: News Release April 8, 2009
8 Apr 2009 ... April 8, 2009 -- Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. ...
http://www.gene.com/gene/news/press-releases/display.do?meth...

FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. ...
8 Apr 2009 ... Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of ...
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc...

RAPTIVA USPI
been observed in patients treated with RAPTIVA (see WARNINGS and. ADVERSE REACTIONS). ... Each single-use vial of RAPTIVA contains 150 mg of efalizumab,
...
http://www.gene.com/gene/products/information/pdf/raptiva-pr...

FDA Public Health Advisory Updated Safety Information about ...
19 Feb 2009 ... Since the approval of Raptiva (efalizumab) in October 2003, the FDA has ... Raptiva increases the risk of PML. Longer, continuous use may ...
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/u...

Genentech: Investors: Raptiva - Historical Sales
Skip to Content for Raptiva - Historical Sales Menu for Raptiva - Historical Sales About Us Menu Research Menu Development Menu Medicines Menu Investors ...
http://www.gene.com/gene/ir/financials/historical/raptiva.ht...

Efalizumab - Wikipedia, the free encyclopedia
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to treat psoriasis. As its name implies, it is a recombinant humanized
...
http://en.wikipedia.org/wiki/Efalizumab...

Raptiva (efalizumab) Feb 2009
[UPDATE 04/08/2009] Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...

Genentech: Newsroom: Press Releases: News Release December 23, 2002
I believe that if approved, Raptiva will make a significant, ... Raptiva is designed to inhibit the adhesion of T-lymphocytes to other cell types by ...
http://www.gene.com/gene/news/press-releases/detail.jsp?deta...

VOLUNTARY U.S. MARKET WITHDRAWAL OF RAPTIVA® (efalizumab)
8 Apr 2009 ... voluntary withdrawal of the psoriasis medication RAPTIVA ... clinical benefit from RAPTIVA, the balance between benefit and risk in the ...
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformati...

FDA Safety Changes: Visicol, OsmoPrep, DiaBeta, Raptiva
The FDA has approved safety labeling revisions for sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous tablets (Visicol and ...
http://www.medscape.com/viewarticle/702471...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.